**Policy Statement** Organizational Principles to Guide and Define the Child Health Care System and/or Improve the Health of all Children

**COVID-19 Vaccines in Children and Adolescents**

Committee on Infectious Diseases

Vaccines are safe and effective in protecting individuals and populations against infectious diseases. New vaccines are evaluated by a long-standing, rigorous, and transparent process through the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) by which safety and efficacy data are reviewed prior to authorization and recommendation.

**Recommendations**

The American Academy of Pediatrics (AAP) recommends the following related to COVID-19 vaccine in children and adolescents:

- The AAP recommends COVID-19 vaccination for all children and adolescents 12 years of age and older who do not have contraindications using a COVID-19 vaccine authorized for use for their age.
• Any COVID-19 vaccine authorized through Emergency Use Authorization by the FDA, recommended by the CDC, and appropriate by age and health status can be used for COVID-19 vaccination in children and adolescents.

• Given the importance of routine vaccination and the need for rapid uptake of COVID-19 vaccines, the AAP supports coadministration of routine childhood and adolescent immunizations with COVID-19 vaccines (or vaccination in the days before or after) for children and adolescents who are behind on or due for immunizations (based on the CDC/AAP Recommended Child and Adolescent Immunization Schedule) and/or at increased risk from vaccine-preventable diseases.

COMMITTEE ON INFECTIOUS DISEASES, 2020-2021
Yvonne A. Maldonado, MD, FAAP, Chairperson
Sean T. O’Leary, MD, MPH, FAAP, Vice Chairperson
Ritu Banerjee, MD, PhD, FAAP
James D. Campbell, MD, MS, FAAP
Mary T. Caserta, MD, FAAP
Jeffrey S. Gerber, MD, PhD, FAAP
Athena P. Kourtis, MD, PhD, MPH, FAAP
Ruth Lynfield, MD, FAAP, Red Book Associate Editor
Flor M. Munoz, MD, MSc, FAAP
Dawn Nolt, MD, MPH, FAAP
Adam J. Ratner, MD, MPH, FAAP
Samir S. Shah, MD, MSCE, FAAP
William J. Steinbach, MD, FAAP
Kenneth M. Zangwill, MD, FAAP
Theoklis E. Zaoutis, MD, MSCE, FAAP
EX OFFICIO
David W. Kimberlin, MD, FAAP – Red Book Editor
Elizabeth D. Barnett MD, FAAP – Red Book Associate Editor
Mark H. Sawyer, MD, FAAP – Red Book Associate Editor
Henry H. Bernstein, DO, MHCM, FAAP – Red Book Online Associate Editor
H. Cody Meissner, MD, FAAP – Visual Red Book Associate Editor

LIAISONS
Amanda C. Cohn, MD, FAAP, Centers for Disease Control and Prevention
Karen M. Farizo, MD, US Food and Drug Administration
Natasha B. Halasa, MD, MPH, FAAP, Pediatric Infectious Diseases Society
David Kim, MD, HHS Office of Infectious Disease and HIV/AIDS Policy
Eduardo López Medina, MD, MSc, Sociedad Latinoamericana de Infectologia Pediatrica
Denee Moore, MD, FAAFP, American Academy of Family Physicians
Scot B. Moore, MD, FAAP, Committee on Practice Ambulatory Medicine
Lakshmi Panagiotakopoulos, MD, MPH, FAAP, Centers for Disease Control and Prevention
Laura Sauvé, MD, FCPS, Canadian Paediatric Society
Neil S. Silverman, MD, American College of Obstetricians and Gynecologists
Jeffrey R. Starke, MD, FAAP, American Thoracic Society
Kay M. Tomashek, MD, MPH, DTM, National Institutes of Health

STAFF
Jennifer M. Frantz, MPH

This document is copyrighted and is property of the American Academy of Pediatrics and its Board of Directors. All authors have filed conflict of interest statements with the American Academy of Pediatrics. Any conflicts have been resolved through a process approved by the Board of Directors. The American Academy of Pediatrics has neither solicited nor accepted any commercial involvement in the development of the content of this publication.
Policy statements from the American Academy of Pediatrics benefit from expertise and resources of liaisons and internal (AAP) and external reviewers. However, policy statements from the American Academy of Pediatrics may not reflect the views of the liaisons or the organizations or government agencies that they represent.

The guidance in this statement does not indicate an exclusive course of treatment or serve as a standard of medical care. Variations, taking into account individual circumstances, may be appropriate.

All policy statements from the American Academy of Pediatrics automatically expire 5 years after publication unless reaffirmed, revised, or retired at or before that time.

FUNDING: No external funding.

CONTRIBUTORS’ STATEMENT:

FINANCIAL DISCLOSURE: The authors have indicated they do not have a financial relationship relevant to this article to disclose.

POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential conflicts of interest to disclose.
COVID-19 Vaccines in Children and Adolescents
Committee on Infectious Diseases
Pediatrics originally published online May 12, 2021;

Updated Information & Services
including high resolution figures, can be found at:
http://pediatrics.aappublications.org/content/early/2021/05/11/peds.2021-05
2336.citation

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://www.aappublications.org/site/misc/Permissions.xhtml

Reprints
Information about ordering reprints can be found online:
http://www.aappublications.org/site/misc/reprints.xhtml
COVID-19 Vaccines in Children and Adolescents
Committee on Infectious Diseases
Pediatrics originally published online May 12, 2021;

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://pediatrics.aappublications.org/content/early/2021/05/11/peds.2021-052336.citation